Bio + Health

Investing in Pomelo Care

Vineeta Agarwala Posted June 8, 2023

“In the United States of America, in the 21st century, being pregnant and giving birth should not carry such great risk. But the truth is…before, during, and after childbirth, women in our nation are dying at a higher rate than any other developed nation in our world. And we know that, for some women, the risk is much higher. When we know that…we need to do something about it.”

– Vice President Kamala Harris, at the Maternal Day of Action Summit

A personal story

I am personally alive thanks to heroic maternal care. My mother was astutely diagnosed with severe preeclampsia, necessitating an emergency airlift and delivery at 29 weeks gestation at an academic medical center in rural Pennsylvania. My entry into the world started with a harrowing 12-week NICU stay. A smart care team and medical innovation like surfactant (discovered just a few years prior for use in preterm babies!) saved my life–and my mother’s life.

Fast forward a few decades later–and in a full circle moment, I was diagnosed with preeclampsia during my own first pregnancy. Even as a physician myself, with outstanding obstetric care, my journey as a new mom felt bewildering, fragmented, and seemingly devoid of modern technology. I tapered off blood pressure medications myself. The postpartum depression survey felt so cold and impersonal that just the act of filling it out made me upset. I couldn’t stop thinking what a mom with less support would do–what about single moms, moms with multiple kids at home, moms without a blood pressure cuff at home, moms without a PCP, or moms lacking resources for transportation to their OB’s office? I started paying attention to every startup, every non-profit and government initiative, and every innovator in the maternal health space.

Pomelo, like the fruit: Extra layers of protection

A few years later, in early 2021, I got a call from Marta, with whom I had previously worked closely at Flatiron Health. She was widely known as a “get stuff done” business development leader and key member of the Flatiron executive leadership team. She was now a mom, too. And, she was about to jump in and become a startup founder/CEO. “I’m thinking about value-based maternity and neonatal care. Want to hear more?”

By this point, I hardly needed to hear more to be ecstatic. I couldn’t imagine a more effective and purpose-driven operator than Marta for any business–but especially this one. It was also painfully clear that too many growing families in America struggle–and as VP Harris recently highlighted, the maternal mortality rate in the US exceeds that of other high-income countries worldwide by a significant margin. That’s despite spending twice as much–an irony that is begging for new technology, care model innovation, and value-based payment rail redesign.

“We’re calling it Pomelo,” Marta said. “Like the fruit. It’s a reference to the super thick protective peel that protects the fruit inside.” I loved the idea of a company that paid homage every day to moms (aren’t we all courageous human pomelos!). I also loved that in Marta’s vision, the company would in some sense be a pomelo to our existing healthcare system–a protective care model that wraps around existing obstetrics providers, NICUs and labor & delivery wards, Medicaid plans, commercial insurance plans, and employers–to continuously improve the maternal and neonatal care journey for patients, provide always-on triage, and lower the catastrophic suffering and cost associated with poor outcomes.

Our early conversations all took place during the early part of the pandemic, while Marta was actually running a 9-month long customer empathy exercise while pregnant herself with her second child in rural Georgia, over an hour away from an OB! Unable to meet in-person, we sent Marta a crate of grapefruits via Instacart, emailed her a recipe for a pomelo basil mocktail, and got together over “Zoom drinks” to shake hands on co-leading the company’s Seed financing alongside fantastic partners at First Round Capital.

So we need to “do something” about maternal health–but what?

Value-based care models are proliferating across healthcare, but maternity presents some particularly unique opportunities–and unique challenges. Unlike primary care, and unlike chronic disease management, the maternity care journey has a very clear, near-term endpoint, with a clear definition of success: Healthy delivery for mom and baby! This creates the opportunity for nimble care model iteration, innovative adoption of technology (e.g., from risk prediction to remote monitoring to symptom management), and relatively rapid ROI demonstration for payor and employer partners.

However, it also necessitates a deep commitment to integrate with our existing healthcare fabric: Obstetricians practicing all over the country, hospitals, health systems, labor & delivery wards, NICUs, and existing maternal care programs. These represent an expensive and valuable care delivery infrastructure without which nearly 4 million babies simply cannot be safely born every year in the US. Especially for high-risk pregnancies and high-risk moms, this infrastructure is essential.

As we have seen the Pomelo team build out their virtual clinic, care model, and software platform, they are dedicated to a few key principles which we believe are absolutely critical to building a scalable company in this space.

  • Deliver 24/7 care for both mom AND baby. Maternal and neonatal care go hand-in-hand, and a trusted relationship with patient families can and should serve both patients. Cost savings from better maternal care are also often realized in neonatal care.
  • Enable rather than replace existing OB providers. For those who have read my prior investment blog posts, you know that I love enablement business models. They allow a company like Pomelo to empower capable physicians already embedded in their communities, avoid the cost structure of becoming the obstetrics office/birthing center, and drive savings with an efficient wrapper care model.
  • Build a solution that pays for itself (via savings to payors and employers), and remains free to patients and individual providers. Socioeconomic inequality and the inability to pay for appropriate care is a driver of the maternal health crisis, and adding out-of-pocket costs to patients is not a sustainable path forward.
  • Use cutting edge software and technology to do all of the above. Look for every opportunity available to make our care more available, more accurate, more actionable, and ultimately more impactful. Use data to understand what is working, and what is not.

We are delighted to see the Pomelo team scale their offering towards serving thousands and even millions of moms, babies, and growing families across the country, across every part of our diverse society. It is a privilege to lead Pomelo’s Series A and serve on the company’s board. Join us!

Want More a16z Bio + Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Learn More
Recommended For You
Infra

new Investing in Deeptune

Marco Mascorro and Martin Casado
Growth

Investing in Mind Robotics

Sarah Wang
Growth

Investing in Nexthop AI

Raghu Raghuram, Shangda Xu, and Guido Appenzeller
Fintech

Investing in Lio

Seema Amble, James da Costa, Eric Zhou, and Brian Roberts
Bio + Health

Investing in Ease

Daisy Wolf, Anish Acharya, and Eva Steinman

Want More Bio+Health?

Insights, analysis, and additional reading on bio and health, and how both are shaping our future.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.